BNTX:NASDAQ
BioNTech SE - ADR
96,66 US$
arrow_downward
-0,19%(-0,18) 1D
2 ოქტ, 13:06:43 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
97,35 US$
High
98,00 US$
Low
96,22 US$
Mkt. cap
24,28 მლრდ.
Avg. vol.
1,19 მლნ.
Volume
363,51 ათ.
52-wk high
123,98 US$
52-wk low
79,52 US$
EPS
-7,54 US$
Beta
1,22
Shares outstanding
251,20 მლნ.
No. of employees
8 ათ.
Open
97,35 US$
High
98,00 US$
Low
96,22 US$
Mkt. cap
24,28 მლრდ.
Avg. vol.
1,19 მლნ.
Volume
363,51 ათ.
52-wk high
123,98 US$
52-wk low
79,52 US$
EPS
-7,54 US$
Beta
1,22
Shares outstanding
251,20 მლნ.
No. of employees
8 ათ.
News stories
From web sources and news partners
AD HOC NEWS
·
8 წუთის წინ
BioNTech stock after-hours at EUR 86.05: minus 0.12 percent versus prior close
AD HOC NEWS
·
2 საათის წინ
Morgan Stanley sets USD 115 target for BioNTech stock
AD HOC NEWS
·
1 დღის წინ
BioNTech stock after-hours at EUR 87.00: plus 0.29 percent
Zacks
·
2 დღის წინ
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR